StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.18−0.35 (-10.04%)

Close on Nov 17, 2026Market cap $143.45MP/E –Yield –

GT Biopharma cash

Cash and short-term investments held at the end of each period.

GT Biopharma's cash was $4.96M at Jun 30, 2026. For fiscal 2025 it was $6.81M, up 68.4% from the year before. Over ten years it grew 64.5% a year on average. The highest annual figure on record is $32.00M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.81M+68.4%
FY2024Dec 31, 2024$4.04M-71.1%
FY2023Dec 31, 2023$14.00M-15.2%
FY2022Dec 31, 2022$16.51M-48.4%
FY2021Dec 31, 2021$32.00M+504.1%
FY2020Dec 31, 2020$5.30M+18817.9%
FY2019Dec 31, 2019$28.00K-53.3%
FY2018Dec 31, 2018$60.00K-89.6%
FY2017Dec 31, 2017$576.00K+2931.6%
FY2016Dec 31, 2016$19.00K-59.6%
FY2015Dec 31, 2015$47.00K-94.5%
FY2014Dec 31, 2014$855.00K+1888.4%
FY2013Dec 31, 2013$43.00K-65.0%
FY2012Dec 31, 2012$123.00K+33.7%
FY2011Dec 31, 2011$92.00K+70.4%
FY2010Dec 31, 2010$54.00K-95.8%
FY2009Dec 31, 2009$1.29M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.96M-6.8%
Q1 FY2026Mar 31, 2026$8.92M+263.0%
Q4 FY2025Dec 31, 2025$6.81M+68.4%
Q3 FY2025Sep 30, 2025$2.53M-61.2%
Q2 FY2025Jun 30, 2025$5.32M-42.2%
Q1 FY2025Mar 31, 2025$2.46M-74.9%
Q4 FY2024Dec 31, 2024$4.04M-71.1%
Q3 FY2024Sep 30, 2024$6.51M-59.3%
Q2 FY2024Jun 30, 2024$9.20M-48.9%
Q1 FY2024Mar 31, 2024$9.80M-50.8%
Q4 FY2023Dec 31, 2023$14.00M-15.2%
Q3 FY2023Sep 30, 2023$16.00M+540.0%
Q2 FY2023Jun 30, 2023$18.00M+233.3%
Q1 FY2023Mar 31, 2023$19.90M+172.6%
Q4 FY2022Dec 31, 2022$16.51M-48.4%
Q3 FY2022Sep 30, 2022$2.50M-35.9%
Q2 FY2022Jun 30, 2022$5.40M-86.3%
Q1 FY2022Mar 31, 2022$7.30M-73.5%
Q4 FY2021Dec 31, 2021$32.00M+504.1%
Q3 FY2021Sep 30, 2021$3.90M+1014.3%
Q2 FY2021Jun 30, 2021$39.51M+4542.2%
Q1 FY2021Mar 31, 2021$27.56M+551000.0%
Q4 FY2020Dec 31, 2020$5.30M+18817.9%
Q3 FY2020Sep 30, 2020$350.00K+11.8%
Q2 FY2020Jun 30, 2020$851.00K+222.3%
Q1 FY2020Mar 31, 2020$5.00K-90.2%
Q4 FY2019Dec 31, 2019$28.00K-53.3%
Q3 FY2019Sep 30, 2019$313.00K-74.6%
Q2 FY2019Jun 30, 2019$264.00K-75.9%
Q1 FY2019Mar 31, 2019$51.00K-98.2%
Q4 FY2018Dec 31, 2018$60.00K-89.6%
Q3 FY2018Sep 30, 2018$1.23M-54.9%
Q2 FY2018Jun 30, 2018$1.10M+2710.3%
Q1 FY2018Mar 31, 2018$2.87M+1121.3%
Q4 FY2017Dec 31, 2017$576.00K+2931.6%
Q3 FY2017Sep 30, 2017$2.73M+1674.0%
Q2 FY2017Jun 30, 2017$39.00K–
Q1 FY2017Mar 31, 2017$235.00K–
Q4 FY2016Dec 31, 2016$19.00K–
Q3 FY2016Sep 30, 2016$154.00K–

More GT Biopharma figures

See a number that looks wrong?